Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Jazz Pharmaceuticals, Inc
483
•Jazz Pharmaceuticals, Inc•May 6, 2011

Jazz Pharmaceuticals, Inc – FDA 483, May 6, 2011

Record Details

This FDA Form 483 was issued to Jazz Pharmaceuticals, Inc., a sponsor establishment located at 3180 Porter Dr, Palo Alto, CA, following an inspection from April 27, 2011, to May 6, 2011. The inspection identified three observations related to adverse drug experience reporting and procedures.

Observation 1 states that not all serious and unexpected adverse drug experiences were reported to the FDA within 15 calendar days. Specifically, 74 confirmed death reports for the drug product Xyrem, received and retained by the firm's specialty pharmacy between November 2002 and April 2011, were not expeditiously reported, with some being more than 2000 days late. These reports were previously undetected through the firm's monitoring of its specialty pharmacy.

Observation 2 indicates that written procedures for the surveillance, receipt, evaluation, and reporting of post-marketing adverse drug experiences to the FDA were not developed. This includes a lack of approved procedures for: verifying and monitoring third-party CROs and specialty pharmacies for adverse event data; determining if an event is serious or expected/unexpected; extracting and entering information into the electronic drug safety database; documenting and reporting follow-up information; preparing periodic safety reports; and documenting job-related employee training for drug safety and pharmacovigilance activities. This deficiency was highlighted by the 74 undetected death reports held by the specialty

Company
Jazz Pharmaceuticals, Inc
Inspection date
May 6, 2011
Product type
Other
Office
San Francisco District Office
Person
  • Daniel J. Roberts ( Assistant Country Director (USFDA India Office Drug Program))
View Company Profile

ID · 65734b80-f875-4342-851d-9760f02eecbc

Violation Codes2
21 CFR 331(c)21 U.S.C. 324(a)(4)

Full citation text and observation details available on the Dashboard.

Other documents for Jazz Pharmaceuticals, Inc
  • 483 - 2019-06-10June 10, 2019
  • 483 - 2016-01-27January 27, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Jazz Pharmaceuticals, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.